Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endomorphins interact with tachykinin receptors.

Piotr Kosson1, Iwona Bonney, Daniel B Carr

  • 1Medical Research Centre, Polish Academy of Sciences, 02106 Warsaw, Poland.

Peptides
|August 23, 2005
PubMed
Summary

Endomorphins exhibit unique pharmacological effects due to a dual action. Beyond their opioid activity, they possess weak antagonist properties at tachykinin NK1 and NK2 receptors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral Ketamine for Chronic Pain: Towards an Evidence-Based Dosing Regimen.

Journal of pain research·2026
Same author

Chirality and Rigidity in Triazole-Modified Peptidomimetics Interacting with Neuropilin-1.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Stapling of leu-enkephalin analogs with bifunctional reagents for prolonged analgesic activity.

Chemical communications (Cambridge, England)·2024
Same author

The psychometric strength and patient centeredness of the Defense and Veterans Pain Rating Scale.

Pain medicine (Malden, Mass.)·2023
Same author

Gα<sub>i</sub>-derived peptide binds the µ-opioid receptor.

Pharmacological reports : PR·2023
Same author

Optimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and Recommendations.

The journal of pain·2022

Area of Science:

  • Pharmacology
  • Neuroscience
  • Receptor Binding Assays

Background:

  • Endomorphins are endogenous opioid peptides with significant roles in pain modulation.
  • Previous studies noted distinct pharmacological profiles for endomorphins compared to other MOR-selective ligands.
  • Variations in the effects of endomorphin I and endomorphin II have also been observed.

Purpose of the Study:

  • To investigate the hypothesis that observed differences in endomorphin activity stem from a non-opioid mechanism.
  • To explore the potential antagonist properties of endomorphins at tachykinin receptors.
  • To elucidate the dual pharmacological nature of endomorphins.

Main Methods:

  • Comparative analysis of endomorphin pharmacology with other MOR ligands.
  • Assessment of endomorphin interactions with tachykinin NK1 and NK2 receptors.
  • Pharmacological assays to determine opioid and non-opioid receptor activities.

Main Results:

  • Endomorphins display unique pharmacological effects not solely attributable to MOR agonism.
  • Evidence suggests endomorphins possess weak antagonist activity at tachykinin NK1 and NK2 receptors.
  • This dual action potentially explains discrepancies noted in prior endomorphin research.

Conclusions:

  • The distinct pharmacological profile of endomorphins is likely due to a combination of MOR agonism and weak tachykinin NK1/NK2 receptor antagonism.
  • This dual property offers a novel perspective on endomorphin function and receptor interactions.
  • Further research is warranted to fully characterize the implications of this dual activity in physiological and pathological contexts.

Related Experiment Videos